Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform

TOKYO, April 14, 2025 /PRNewswire/ — PRISM BioLab, Co. Ltd. (“PRISM BioLab”), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a drug discovery collaboration with Elix, Inc. (“Elix”), effective April 1, 2025.

This partnership will accelerate research on these challenging molecular targets by combining PRISM BioLab’s proprietary peptide mimetic technology for controlling protein-protein interactions with Elix’s cutting-edge AI drug discovery platform.

In drug discovery, generating a clinical candidate molecule typically takes long time and requires synthesis of hundreds to thousands of compounds, making research and development efficiency a critical challenge. Through this partnership, PRISM BioLab’s proprietary small molecule peptide-mimetic PepMetics® technology will be integrated with Elix’s AI drug discovery platform “Elix Discovery™.” This collaboration will expand the AI search range to include previously unconsidered small molecules, enabling efficient identification of promising compounds for traditionally difficult targets and accelerating the creation of breakthrough drug candidates. By leveraging both companies’ AI capabilities and medicinal chemistry expertise, the partnership aims to reduce time and costs and improve success rate of drug discovery, ultimately delivering innovative treatments for unmet medical needs.

Comments from Executives

Elix co-founder and CEO Shinya Yuki, Ph.D.:

In our previous pilot project with PRISM BioLab, we achieved breakthrough results by creating novel compound candidates with an efficiency that would be unimaginable using conventional approaches. This success clearly demonstrated that the combination of our companies’ technologies and expertise holds tremendous potential in drug discovery. I am genuinely looking forward to this business partnership, where we can leverage our complementary strengths to pursue outcomes that neither company could achieve alone.

PRISM BioLab CEO Dai Takehara:

As we challenge ourselves to ‘create new areas of drug discovery’ with peptide-mimetic small molecules, AI utilization is essential. We expect our efforts to be significantly accelerated through collaboration with Elix, whose mission is to ‘rethink drug discovery.’ Our pilot project has already demonstrated the synergistic effect of our technologies and team collaboration, and we will continue to pursue the early creation of groundbreaking new drugs together.

PRISM BioLab CTO Tatsuya Toma Ph.D.:

Improving drug discovery efficiency is an eternal challenge. Delivering better medicines to patients and healthcare professionals as quickly as possible requires innovation. Our PepMetics® technology has characteristics that are highly compatible with AI applications. Elix is not only a professional in AI and machine learning but also expanding their knowledge and understanding of drug discovery while maintaining a flexible corporate culture. They have shown great interest in PepMetics® features, and I believe we can advance comprehensive drug discovery research together, leveraging PepMetics® characteristics to accelerate the process.

About Elix

Elix is an AI drug discovery company with the mission of “Rethinking drug discovery”. Through their flagship software platform, Elix Discovery™, and collaborative consulting engagements, they work with leading pharmaceutical companies and biotech startups to reduce the enormous costs and time associated with drug discovery, while improving the rate of successful outcomes. They achieve these goals via their company’s unique blend of AI engineering and medicinal chemistry expertise that allows them to stay at the forefront of development in both fields, and offer the solutions of tomorrow to the problems of today.

https://www.elix-inc.com/ 

About PRISM BioLab

PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics® technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics.

PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceutical Co., Ltd. are in clinical development for cancer and liver disease, respectively.

www.prismbiolab.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/prism-biolab-and-elix-join-forces-to-accelerate-ai-driven-drug-discovery-for-protein-protein-interaction-targets-302426497.html

SOURCE PRISM BioLab Co., Ltd.

BERLIN, April 14, 2025 /PRNewswire/ — Riad Corporation, a leading AI-powered travel technology company, successfully launched its flagship product, RIA 1.0, at ITB Berlin 2025, one of the world’s largest travel trade shows. The company attracted over 300 visitors to its booth and secured 150 enterprise client sign-ups during the three-day event, marking a major milestone for its global expansion.

RIA 1.0 is an advanced AI platform that fully automates group hotel reservations, tailored for travel agencies and corporate clients handling complex requirements. Unlike traditional systems, RIA enables both direct bookings and customized group requests, processed entirely by AI without manual work. The platform simplifies large-scale, multi-hotel bookings — tasks that usually take days — completing them in minutes.

During ITB Berlin, Riad Corporation presented live demonstrations showing how RIA’s AI engine handles diverse, high-volume booking scenarios. Attendees praised its intuitive interface, seamless integration, and real-time responses to specific client needs, including corporate events, MICE bookings, and incentive groups.

Mike Lee, CEO of Riad Corporation, commented, “Meeting so many global partners at ITB Berlin was truly meaningful, and we are proud to showcase our technology to the world,” adding, “We will continue to focus on R&D to deliver stronger innovations and achieve greater success globally.”

In addition, Riad Corporation announced plans to launch AI-based group flight booking services later this year, transforming RIA into a comprehensive group travel platform covering both hotels and flights.

RIA has already gained momentum in Southeast Asia, with over 800 enterprise clients, and aims to reach 2,000 clients by the end of 2025.

Riad Corporation’s strong debut at ITB Berlin reflects rising demand for AI-driven solutions in travel. As group travel grows more complex, RIA 1.0 is positioned to lead the market with unmatched speed, accuracy, and automation.

For more information about Riad’s solution RIA, visit ‘www.ria-travel.com‘.

Photo – https://mma.prnewswire.com/media/2646943/ria.jpg
Logo – https://mma.prnewswire.com/media/2646944/RIAD_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/riad-corp-reveals-ai-powered-hotel-group-booking-platform-ria-at-itb-berlin-2025-302424402.html

Order bookings exceed 7 GW in FY25Total India projects (commissioned as well as under installation) cross 13 GWOver 20 GW local manufacturing capacity for key components

BENGALURU, India , April 14, 2025 /PRNewswire/ — GameChange Solar, a leading global supplier of solar tracker and fixed-tilt racking technology, has closed FY 25 on a strong note in the Indian market, with total order bookings of 7 GW. Of this, nearly 2 GW of tracker orders were signed in Q4 FY 25, marking a robust end to the financial year.

With this milestone, GameChange Solar’s total projects in India (commissioned as well as under installation) have now exceeded 13 GW, reinforcing its position as a trusted technology partner in the country’s growing utility-scale solar segment. A significant portion of these new orders represents repeat business from clients, reflecting GameChange Solar’s proven performance, consistent execution, and customer-first approach.

To support this growth, the company’s local manufacturing capacity for key components has surpassed 20 GW annually, enabling faster deliveries and stronger alignment with project timelines.

“India continues to be one of the most exciting and dynamic solar markets globally, and this strong finish to FY 25 reflects the valued relationships we’ve built with our customers and the reliability of our Genius Tracker™ systems,” said Vikas Bansal, President – International at GameChange Solar. “What’s particularly encouraging is the consistency of demand across states, developer profiles, and project sizes – from first-time engagements to repeat orders. It shows that the market isn’t just growing, it’s maturing, and there’s a clear preference for scalable, execution-focused partners who can deliver at speed.”

GameChange Solar’s Genius Tracker™ solutions are engineered for high-wind, high-heat environments – combining speed, structural durability, and precision tracking to maximize output and reduce project timelines. Their versatility makes them ideally suited for India’s diverse terrains and aggressive commissioning schedules.

For more information about GameChange Solar and its solar tracking solutions, visit www.gamechangesolar.com. 

About GameChange Solar

GameChange is the second largest global provider of solar tracker solutions used in utility-scale and ground-mounted distributed generation solar projects around the world. We have delivered over 43 GW of solar tracker and fixed tilt systems that combine fast installation, bankable quality, and unbeatable value through superior engineering, innovative design, and high-volume manufacturing. Our products enable solar panels at power plants to follow the sun’s movement across the sky and optimize plant performance while protecting the array from damaging weather conditions.

Media Contact

Nisha Wadhwani

Lead – Marketing, GameChange Solar

nisha.wadhwani@gamechangesolar.com

Logo – https://mma.prnewswire.com/media/1592922/GameChange_Solar_Logo.jpg

View original content:https://www.prnewswire.com/in/news-releases/gamechange-solar-closes-fy-25-in-india-with-strong-order-momentum-302426929.html